Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine

Breast Cancer Clinical Trial

Official title:

Pilot Study to Test Uniformity of Transdermal Drug Delivery to the Breast Using Diclofenac Epolamine as a Model

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01380353
• Other study ID #: NU 10B05
• Secondary ID: STU00042939
• Status: Completed
• Phase: Early Phase 1
• Start date: June 2011
• Est. completion date: November 12, 2012

Study information

• Verified date: February 2020
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to look for ways to improve breast cancer treatment by giving breast cancer drugs through the skin of the breast.

The drug used in this study is a diclofenac epolamine patch and is a nonsteroid anti-inflammatory pain reliever. The drug amount that gathers in the breast, after application of a patch to the skin of the breast, will be measured and compared to the amount that is found in the breast when the patch is applied to the skin of the belly.

Description:

This is a randomized study where participants in group 1 will apply the diclofenac epolamine patch to the breast and participants in group 2 will apply the same drug to her abdomen. Participants are instructed to apply a new patch every 12 hours for 3 days. Total participation in this study will be for three days, ending on the day of surgery. On the day of surgery, participants will have blood drawn to measure the level of diclofenac epolamine in the body, and the final patch will be removed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 12, 2012
• Est. primary completion date: November 12, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Women between the ages of 18 and 80 years, undergoing total mastectomy for, with or without axillary surgery for diagnosis or prevention of breast cancer.

• ECOG performance status less than 2.

• Ability to understand and the willingness to sign a written informed consent.

• Participants must have normal organ and marrow function

Exclusion Criteria:

• Prior history of ipsilateral breast radiotherapy.

• Pregnant women and those who will be actively breast-feeding in the preoperative period will be excluded.

• Inability to discontinue aspirin or warfarin use during the period of participation.

• Known allergy to diclofenac epolamine, or aspirin, diclofenac (Cataflam, Voltaren), or another non-steroidal anti-inflammatory drug (NSAID).

• Renal failure

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Diclofenac epolamine patch
Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner [B].

Locations

Country	Name	City	State
United States	Northwestern University	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare concentrations of diclofenac epolamine patch when applied to breast vs. abdomen	The primary objective of this protocol will demonstrate that diclofenac epolamine patch applied to the skin of the breast for three days (1, 2) prior to surgery will result in significantly higher drug concentrations in the breast than the same dose applied to the abdominal skin for the same duration of time.	after 3 days of treatment prior to surgery
Secondary	Determine how the concentrations of the study patch is distributed in the breast.	To establish that the diclofenac epolamine drug concentrations achieved in the breast have no significant fall-off with increasing distance from the site of application. Therefore, uniform therapeutic concentrations are achieved throughout the breast with a single site of local transdermal therapy (LTT).	after three days of treatment prior to surgery